Implementation of guidelines for the management of fungal infections at Besançon University Hospital;Mise en place de recommandations pour la prise en charge des infections fongiques au CHU de Besançon

Journal de Mycologie Medicale

Volumn 14, Issue 4 I, 2004, Pages 185-191

  Leroy, J ^a   Grenouillet, F ^a   Navellou, J C ^a   Fagnoni, P ^a   Muret, P ^a   Deconinck, E ^a   Blasco, G ^a   Henon, T ^a   Khayat, N ^a   Hoen, B ^a   Piarroux, R ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Antitungal agents; Aspergillosis; Febrile neutropenia; Guidelines; Invasive candidiasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CAREGIVER; CLINICAL FEATURE; FEBRILE NEUTROPENIA; HUMAN; MYCOSIS; PRACTICE GUIDELINE; UNIVERSITY HOSPITAL;

EID: 19944426232     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Anonyme. Vfend. Commission de transparence AFSSAPS, Sept. 4, 2002.
2. Anonyme. Cancidas. Commission de transparence AFSSAPS, Jul. 23, 2003.
3. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002;49:21-30.
4. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J. Gentry L, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-72.
5. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
6. Bachmann SP, Ramage G, VandeWalle K, Patterson TF, Wickes BL, Lopez-Ribot JL. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother 2003;47:3657-9.
7. nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Sept. 27-30, 2002. Abstract M-1814, San Diego.
8. Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000;5:120-35.
9. Costa C, Costa JM, Desterke C, Botterel F, Cordonnier C, Bretagne S. Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis. J Clin Microbiol 2002;40:2224-7.
10. De Lastours V, Lefort A, Zappa M, Dufour V, Belmatoug N, Fantin B. Two cases of cerebral aspergillosis successfully treated with voriconazole. Eur J Clin Microbiol Infect Dis 2003;22:297-9.
11. De Pauw BE. New antifungal agents and preparations. Int J Antimicrob Agents 2000;16:147-50.
12. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002;49:31-6.
13. Eggimann P, Pittet D. Candidoses invasives en réanimation. Schweiz Med Wochenschr 2000;130:1525-37.
14. Freydiere AM, Buchaille L, Guinet R, Gille Y. Evaluation of latex reagents for rapid identification of Candida albicans and C. krusei colonies. J Clin Microbiol 1997;35:877-80.
15. Freydiere AM, Guinet R, Boiron P. Yeast identification in the clinical microbiology laboratory: phenotypical methods. Med Mycol 2001; 39:9-33.
16. Freydiere AM, Robert R, Ploton C, Marot-Leblond A, Monerau F, Vandenesch F. Rapid identification of Candida glabrata with a new commercial test, GLABRATA RTT. J Clin Microbiol 2003;41:3861-3.
17. Gatbois E, Adjaoud D, Larroquet M, Zerah M, Ducou Le Pointe H, Vu Thien H, et al. Successful treatment of disseminated aspergillosis by caspofungin and voriconazole in a leukemic child. J Mycol Med 2002; 12:90-92.
18. nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Sept. 27-30, 2002. Abstract M-860, San Diego.
19. Graybill JR, Bocanegra R, Najvar LK, Hernandez S, Larsen RA. Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis. Antimicrob Agents Chemother 2003;47:2373-5.
20. Grillot R, Lortholary O. Nosologie: du laboratoire au malade. Les candidoses systémiques. JIDIF. Optimed. ed. Paris: 2001. pp. 41-68.
21. Groll AH, Gea-Banacloche JC, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003;17:159-91.
22. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000:182:274-82.
23. Groll AH, Walsh TJ. Antifungal chemotherapy: advances and perspectives. Swiss Med Wkly 2002;132:303-11.
24. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
25. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7.
26. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002;46: 2564-8.
27. Loeffler J, Stevens DA. Antifungal drug resistance. Clin Infect Dis 2003;36:31-41.
28. nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Sept. 27-30. 2002. Abstract M-868, San Diego.
29. Manavathu EK, Ganesan LT, Cutright JL, Chandrasekar PH. In vitro antifungal activity of voriconazole in two-drug combination with micafungin. caspofungin and amphotericin B. 41nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Dec. 16-19, 2001. Abstract J-125, Chicago.
30. Martino P, Girmenia C, Venditti M, Micozzi A, Santilli S, Burgio VL, et al. Candida colonization and systemic infection in neutropenic patients. A retrospective study. Cancer 1989;64:2030-4.
31. Mermel LA, Fair BM, Sherertz RJ, Raad I, O'Grady N, Harris JS, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001;32:1249-72.
32. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
33. Noskin GA, Pietrelli L, Coffey G, Gurwith M, Liang LJ. Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 1998;26:461-7.
34. Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002;34:591-9.
35. nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Sept. 27-30, 2002. Abstract M-856. San Diego.
36. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002;46:3039-41.
37. Petraitis V, Petraitiene R, Sarafandi A, Kelaher A, Lyman C, Casler H, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003;187:1834-43.
38. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751-8.
39. Powers JH, Dixon CA, Goldberger MJ. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N Engl J Med 2002;346:289-90.
40. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000;30:662-78.
41. Rodriguez CA, Patrick CC. New therapeutic options for invasive fungal diseases. Sem Ped Infect Dis 2001;72:301-308.
42. Sendid B, Poirot JL, Tabouret M, Caillot D, Bonnin A, Camus D, et al. Combined detection of mannanemia and anti-mannan antibodies for the diagnosis of systemic infection determined by the most pathogenic Candida species. J Med Microbiol 2002;57:1-10.
43. Sendid B, Tabouret M, Poirot JL, Mathieu D, Fruit J, Poulain D. New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis. J Clin Microbiol 1999;37: 1510-17.
44. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 2003;17:113-34.
45. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001;33:1692-6.
46. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000;30:696-709.
47. Stevens DA. Diagnosis of fungal infections: current status. J Antimicrob Chemother 2002;49(Suppl 1):11-9.
48. Thiebaut T, Antal D, Breysse M-C, Pivot C. Refractory invasive fungal infections in patients with hematologic malignancies: combination of new antifungal agents (voriconazole or caspofungin) with amphotericin B. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Sept. 27-30, 2002. Abstract M-859, San Diego.
49. Vincent JL, Anaissie E, Bruining H, Demajo W, El-Ebiary M, Haber J, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in sursical patients under intensive care. Intensive Care Med 1998;24:206-16.
50. rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Sept. 14-17, 2003. Abstract M-1761, Chicago.
51. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-71.
52. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
53. Walsh TJ, Whitcomb P, Piscitelli S, Figg WD, Hill S, Chanock SI, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997;41:1944-8.
54. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31:1155-63.
55. Yeo SF, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev 2002;15:465-84.